Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases

Cell Death Dis. 2022 Mar 17;13(3):248. doi: 10.1038/s41419-022-04688-x.

Abstract

Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR). CD95 is a prototypic DR activated by its cognate ligand CD95L triggering programmed cell death. As a consequence, alterations in the CD95/CD95L pathway have been involved in several disease conditions ranging from autoimmune diseases to inflammation and cancer. CD95L-induced cell death has multiple roles in the immune response since it constitutes one of the mechanisms by which cytotoxic lymphocytes kill their targets, but it is also involved in the process of turning off the immune response. Furthermore, beyond the canonical pro-death signals, CD95L, which can be membrane-bound or soluble, also induces non-apoptotic signaling that contributes to its tumor-promoting and pro-inflammatory roles. The intent of this review is to describe the role of CD95/CD95L in the pathophysiology of cancers, autoimmune diseases and chronic inflammation and to discuss recently patented and emerging therapeutic strategies that exploit/block the CD95/CD95L system in these diseases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / physiology
  • Autoimmune Diseases*
  • Fas Ligand Protein / metabolism
  • Humans
  • Inflammation
  • Neoplasms*
  • fas Receptor / metabolism

Substances

  • Fas Ligand Protein
  • fas Receptor